BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.2M
Cash & Equivalents
$1.3M
Quarterly Burn Rate
$8M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | PHASE2 | Recruiting | 406 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.